Towards Optimal Treatment for High Risk Prostate Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
HYPOPRIME treatment: Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
Study summary
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.
* patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation)
* the tumor will get a higher dose
* androgen deprivation therapy will be reduced as much al possible preventing side effects
Researchers will compare oncological outcome and toxicity.
Eligibility
Primary outcome measure(s)
- Biochemical recurrence free survival — 5 years
rise of PSA 2 ng/ml above nadir - Late gastrointestinal and genito-urinary toxicity, and erectile dysfunction — at 6 months and 2 years
according to CTC-AE v5
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Haaglanden Medical Centre | Leidschendam | South Holland | Recruiting |
More Haaglanden Medical Centre trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06204341 on ClinicalTrials.gov ↗ ← All trials in the Netherlands